UPDATE: Shares of Sagent Pharmaceuticals Respond to Bank of America's Upgrade

By: via Benzinga
In a report published Friday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Sagent Pharmaceuticals (NASDAQ: SGNT ) from Neutral to Buy and lowered the price target from $26.00 to $25.00 noting favorable risk-reward on the stock's pullback. Gilbert commented on the limited downside if Sagent's quarterly performance remains
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.